Arvinas, Inc. (NASDAQ:ARVN) CAO David K. Loomis Sells 1,214 Shares of Stock

Arvinas, Inc. (NASDAQ:ARVN) CAO David K. Loomis sold 1,214 shares of the stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $16.75, for a total transaction of $20,334.50. Following the completion of the sale, the chief accounting officer now directly owns 18,863 shares in the company, valued at approximately $315,955.25. The trade was a 6.05 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Arvinas Stock Up 5.5 %

Arvinas stock opened at $17.67 on Wednesday. The stock has a market cap of $1.21 billion, a price-to-earnings ratio of -6.38 and a beta of 1.88. The business has a 50-day simple moving average of $18.41 and a 200 day simple moving average of $22.80. Arvinas, Inc. has a 52 week low of $16.07 and a 52 week high of $51.51.

Arvinas (NASDAQ:ARVN) last issued its quarterly earnings data on Tuesday, February 11th. The company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($1.07) by $0.44. Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. During the same period last year, the firm posted ($2.53) earnings per share. On average, research analysts anticipate that Arvinas, Inc. will post -3.81 earnings per share for the current year.

Institutional Trading of Arvinas

A number of institutional investors have recently made changes to their positions in ARVN. GF Fund Management CO. LTD. purchased a new position in shares of Arvinas in the fourth quarter worth approximately $28,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Arvinas by 0.7% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 433,531 shares of the company’s stock valued at $8,311,000 after buying an additional 3,047 shares during the last quarter. Voloridge Investment Management LLC bought a new stake in shares of Arvinas during the fourth quarter valued at approximately $749,000. Woodline Partners LP raised its position in shares of Arvinas by 39.2% during the fourth quarter. Woodline Partners LP now owns 692,733 shares of the company’s stock valued at $13,280,000 after buying an additional 194,996 shares during the last quarter. Finally, Twinbeech Capital LP bought a new stake in Arvinas in the fourth quarter worth $3,146,000. Hedge funds and other institutional investors own 95.19% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. Barclays dropped their price objective on shares of Arvinas from $48.00 to $32.00 and set an “overweight” rating on the stock in a research note on Monday, February 3rd. Stifel Nicolaus cut their price objective on shares of Arvinas from $63.00 to $51.00 and set a “buy” rating on the stock in a research note on Wednesday, February 12th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arvinas in a research report on Friday, February 7th. Stephens assumed coverage on Arvinas in a research note on Monday, November 18th. They issued an “overweight” rating and a $55.00 price objective for the company. Finally, Guggenheim reaffirmed a “buy” rating and set a $57.00 price target on shares of Arvinas in a research note on Wednesday, February 12th. Twelve analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $60.00.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.